Dylan P Hartley
Overview
Explore the profile of Dylan P Hartley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bumpers Q, Pipal R, Benz-Weeden A, Brewster 2nd J, Cook A, Crooks A, et al.
J Med Chem
. 2024 Aug;
67(16):14466-14477.
PMID: 39088797
Mesenchymal-epithelial transition factor (MET) is a receptor tyrosine kinase that serves a critical function in numerous developmental, morphogenic, and proliferative signaling pathways. If dysregulated, MET has been shown to be...
2.
Ren L, Moreno D, Baer B, Barbour P, Bettendorf T, Bouhana K, et al.
J Med Chem
. 2024 Jul;
67(15):13019-13032.
PMID: 39077892
Mutant BRAF is one of the most common oncogenic drivers in metastatic melanoma. While first generation BRAF inhibitors are capable of controlling tumors systemically, they are unable to adequately treat...
3.
Hicken E, Brown K, Dwulet N, Gaudino J, Hansen E, Hartley D, et al.
J Med Chem
. 2024 May;
67(11):9759-9771.
PMID: 38820338
HER2 overexpression and amplification have been identified as oncogenic drivers, and the development of therapies to treat tumors harboring these markers has received considerable attention. Activation of HER2 signaling and...
4.
Yaeger R, McKean M, Haq R, Beck J, Taylor M, Cohen J, et al.
Cancer Discov
. 2024 May;
14(9):1599-1611.
PMID: 38691346
RAF inhibitors have transformed treatment for patients with BRAFV600-mutant cancers, but clinical benefit is limited by adaptive induction of ERK signaling, genetic alterations that induce BRAFV600 dimerization, and poor brain...
5.
Drilon A, Sharma M, Johnson M, Yap T, Gadgeel S, Nepert D, et al.
Cancer Discov
. 2023 Jun;
13(8):1789-1801.
PMID: 37269335
Significance: PF-07284892-targeted therapy combinations overcame bypass-signaling-mediated resistance in a clinical setting in which neither component was active on its own. This provides proof of concept of the utility of SHP2...
6.
Fell J, Fischer J, Baer B, Blake J, Bouhana K, Briere D, et al.
J Med Chem
. 2020 Apr;
63(13):6679-6693.
PMID: 32250617
Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the...
7.
Pai R, Ma N, Connor A, Danilenko D, Tarrant J, Salvail D, et al.
Toxicol Sci
. 2016 Feb;
151(2):245-60.
PMID: 26917699
PRO304186, a humanized monoclonal antibody targeting soluble interleukin-17 A and F, was developed for autoimmune and inflammatory disease indications. When administered to cynomolgus monkeys PRO304186 induced unexpected adverse effects characterized...
8.
Diaz D, Ford K, Hartley D, Harstad E, Cain G, Achilles-Poon K, et al.
Toxicol Appl Pharmacol
. 2012 Nov;
266(1):86-94.
PMID: 23142475
Several toxicities are clearly driven by free drug concentrations in plasma, such as toxicities related to on-target exaggerated pharmacology or off-target pharmacological activity associated with receptors, enzymes or ion channels....
9.
Khojasteh S, Hartley D, Ford K, Uppal H, Oishi S, Nelson S
Chem Res Toxicol
. 2012 Oct;
25(11):2301-9.
PMID: 23106769
Pulegone is the major constituent of pennyroyal oil, a folkloric abortifacient that is associated with hepatotoxicity and, in severe cases, death. Cytochrome P450-mediated oxidation of pulegone generates menthofuran, which is...
10.
Diaz D, Allamneni K, Tarrant J, Lewin-Koh S, Pai R, Dhawan P, et al.
Toxicol Sci
. 2011 Oct;
125(1):187-95.
PMID: 21976371
MEK, a kinase downstream of Ras and Raf oncogenes, constitutes a high priority target in oncology research. MEK small molecule inhibitors cause soft tissue mineralization in rats secondary to serum...